ALIM vs. OGI, TELO, IVA, SCPH, GLSI, ACRV, LFCR, CAPR, TRVI, and MCRB
Should you be buying Alimera Sciences stock or one of its competitors? The main competitors of Alimera Sciences include Organigram (OGI), Telomir Pharmaceuticals (TELO), Inventiva (IVA), scPharmaceuticals (SCPH), Greenwich LifeSciences (GLSI), Acrivon Therapeutics (ACRV), Lifecore Biomedical (LFCR), Capricor Therapeutics (CAPR), Trevi Therapeutics (TRVI), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.
Alimera Sciences (NASDAQ:ALIM) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.
Alimera Sciences has higher earnings, but lower revenue than Organigram. Organigram is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.
Alimera Sciences received 159 more outperform votes than Organigram when rated by MarketBeat users. However, 70.61% of users gave Organigram an outperform vote while only 57.70% of users gave Alimera Sciences an outperform vote.
Alimera Sciences has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
Alimera Sciences currently has a consensus price target of $8.00, suggesting a potential upside of 150.00%. Given Alimera Sciences' higher possible upside, equities analysts plainly believe Alimera Sciences is more favorable than Organigram.
99.8% of Alimera Sciences shares are owned by institutional investors. Comparatively, 34.6% of Organigram shares are owned by institutional investors. 31.4% of Alimera Sciences shares are owned by company insiders. Comparatively, 0.1% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Alimera Sciences has a net margin of -23.74% compared to Organigram's net margin of -188.38%. Organigram's return on equity of -40.19% beat Alimera Sciences' return on equity.
In the previous week, Alimera Sciences and Alimera Sciences both had 12 articles in the media. Organigram's average media sentiment score of 0.36 beat Alimera Sciences' score of 0.05 indicating that Organigram is being referred to more favorably in the news media.
Summary
Alimera Sciences beats Organigram on 11 of the 16 factors compared between the two stocks.
Get Alimera Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alimera Sciences Competitors List
Related Companies and Tools
